NASDAQ: EGRX - Eagle Pharmaceuticals, Inc.

Rentabilität für sechs Monate: -90.44%
Sektor: Healthcare

Aktionsplan Eagle Pharmaceuticals, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

weitere details
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2014-02-12
ISIN US2697961082
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.eagleus.com
Цена ао 5.04
Preisänderung pro Tag: -2% (0.5102)
Preisänderung pro Woche: -9.09% (0.55)
Preisänderung pro Monat: -29.58% (0.71)
Preisänderung über 3 Monate: -87.34% (3.95)
Preisänderung über sechs Monate: -90.44% (5.23)
Preisänderung pro Jahr: -90.44% (5.23)
Preisänderung über 3 Jahre: -99.1% (55.42)
Preisänderung über 5 Jahre: -99.11% (56.22)
Preisänderung über 10 Jahre: 0% (0.5)
Preisänderung seit Jahresbeginn: -35.06% (0.77)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 1.2 9
P/BV 1.63 8
P/E 10.67 9
EV/EBITDA 5.92 9
Gesamt: 9

Effizienz

Name Bedeutung Grad
ROA, % 10.8 4
ROE, % 17.39 5
Gesamt: 4.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0.2257

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0.9542 9
Gesamt: 7.2

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 48.43 6
Rentabilität Ebitda, % 91.84 9
Rentabilität EPS, % 30.52 5
Gesamt: 4.4
Weitere Details

Institutionen Volumen Aktie, %
Blackrock Inc. 984908 7.58
Janus Henderson Group PLC 775525 5.97
Brandes Investment Partners L.P. 745080 5.74
Vanguard Group Inc 638124 4.91
Millennium Management LLC 522402 4.02
AQR Capital Management, LLC 493665 3.8
LSV Asset Management 391758 3.02
Morgan Stanley 296864 2.29
Renaissance Technologies, LLC 294450 2.27
Acadian Asset Management. LLC 287555 2.21

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
Royce Quant Small‑Cap Quality Value ETF 0.19827 21.83 1.62596
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.01366 17.58 1.75869
iShares Micro-Cap ETF 0.01037 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.00121 17.47 1.51433



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board 160k 1963 (62 Jahr)
Dr. Valentin R. Curt M.D. Senior Vice President of Clinical Drug Development N/A
Dr. Gaozhong Zhu Ph.D. Senior Vice President of Pharmaceutical Development N/A
Mr. Reed McClung Executive Vice President of Oncology Business Development N/A
Mr. Steven B. Ratoff Interim CFO, Principal Accounting Officer & Director 100k 1943 (82 Jahr)
Mr. Daniel O'Connor Executive VP, Chief Strategy Officer & Head of Corporate Development 1980 (45 Jahre)
Ms. Debra Marie Hussain Senior VP & Head of Commercial 1968 (57 Jahre)

Adresse: United States, Woodcliff Lake. NJ, 50 Tice Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.eagleus.com